tbuckley/cabot-search huggingface dataset:
Toward Real‐Time Blood Pressure Monitoring via High‐Fidelity Iontronic Tonometric Sensors with High Sensitivity and Large Dynamic Ranges
Authors: Qingzhou Wan, Qian Chen, Mark A Freithaler, Sridhar Reddy Velagala, Yihan Liu, Albert C. To, Aman Mahajan, Ramakrishna Mukkamala, Feng Xiong
Journal: Advanced Healthcare Materials (2023)

Continuous, noninvasive blood pressure (CNIBP) monitoring provides valuable hemodynamic information that renders detection of the early onset of cardiovascular diseases. Wearable mechano-electric pressure sensors that mount on the skin are promising candidates for monitoring continuous blood pressure (BP) pulse waveforms due to their excellent conformability, simple sensing mechanisms, and convenient signal acquisition. However, it is challenging to acquire high-fidelity BP pulse waveforms since it requires highly sensitive sensors (sensitivity larger than 4 × 10
Ectopic Pregnancy Risk in Users of Levonorgestrel-Releasing Intrauterine Systems With 52, 19.5, and 13.5 mg of Hormone
Authors: Amani Meaidi, Christian Torp-Pedersen, Øjvind Lidegaard, Lina Steinrud Mørch
Journal: JAMA (2023)

This study assesses the association between use of levonorgestrel intrauterine systems containing 52, 19.5, and 13.5 mg of hormone and ectopic pregnancy in a nationwide cohort study.
Error in Funding/Support Statement
Journal: JAMA Network Open (2023)

Daisuke Hitaka, MD; Satoshi Fujiyama, MD, PhD; Yukiko Nishihama, PhD; Ryota Ishii, PhD; Yusuke Hoshino, MD, PhD; Hiromi Hamada, MD, PhD; Yayoi Miyazono, MD, PhD; Shoji F. Nakayama, MD, PhD; Hidetoshi Takada, MD, PhD
Improving Augmented Reality Through Deep Learning: Real-time Instrument Delineation in Robotic Renal Surgery
Authors: Pieter De Backer, Charles Van Praet, Jente Simoens, Maria Peraire Lores, Heleen Creemers, Kenzo Mestdagh, Charlotte Allaeys, Saar Vermijs, Pietro Piazza, Angelo Mottaran, Carlo A. Bravi, Marco Paciotti, Luca Sarchi, Rui Farinha, Stefano Puliatti, Francesco Cisternino, Federica Ferraguti, Charlotte Debbaut, Geert De Naeyer, Karel Decaestecker, Alexandre Mottrie
Journal: European Urology (2023)

Several barriers prevent the integration and adoption of augmented reality (AR) in robotic renal surgery despite the increased availability of virtual three-dimensional (3D) models. Apart from correct model alignment and deformation, not all instruments are clearly visible in AR. Superimposition of a 3D model on top of the surgical stream, including the instruments, can result in a potentially hazardous surgical situation. We demonstrate real-time instrument detection during AR-guided robot-assisted partial nephrectomy and show the generalization of our algorithm to AR-guided robot-assisted kidney transplantation. We developed an algorithm using deep learning networks to detect all nonorganic items. This algorithm learned to extract this information for 65 927 manually labeled instruments on 15 100 frames. Our setup, which runs on a standalone laptop, was deployed in three different hospitals and used by four different surgeons. Instrument detection is a simple and feasible way to enhance the safety of AR-guided surgery. Future investigations should strive to optimize efficient video processing to minimize the 0.5-s delay currently experienced. General AR applications also need further optimization, including detection and tracking of organ deformation, for full clinical implementation.
Preoperative Hemodialysis Timing and Postoperative Mortality in Patients With End-stage Kidney Disease
Authors: Nirvik Pal, Miklos D. Kertai, Mark Nelson
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IL-6 in the infarcted heart is preferentially formed by fibroblasts and modulated by purinergic signaling
Authors: Christina Alter, Anne-Sophie Henseler, Christoph Owenier, Julia Hesse, Zhaoping Ding, Tobias Lautwein, Jasmin Bahr, Sikander Hayat, Rafael Kramann, Eva Kostenis, Jürgen Scheller, Jürgen Schrader
Journal: Journal of Clinical Investigation (2023)

Plasma IL-6 is elevated after myocardial infarction (MI) and is associated with increased morbidity and mortality. Which cardiac cell type preferentially contributes to IL-6 and how its production is regulated is largely unknown. Here, we studied the cellular source and purinergic regulation of IL-6 formation in a murine MI model. IL-6, measured in various cell types in post MI hearts by qPCR, RNAscope and at protein level, was preferentially formed by fibroblasts (CFs). scRNAseq in infarcted mouse and human hearts confirmed this finding. Adenosine stimulated fibroblast IL-6 formation via A2bR in a Gq-dependent manner. CFs highly expressed Adora2b, rapidly degraded extracellular ATP to AMP but lacked CD73. In mice and humans Adora2B was also mainly expressed by fibroblasts (scRNAseq). Global IL-6 formation was assessed in isolated hearts in mice lacking CD73 on T-cells (CD4CD73-/-) a condition known to be associated with adverse cardiac remodeling. The ischemia-induced release of IL-6 was strongly attenuated in CD4CD73-/- mice, suggesting adenosine-mediated modulation. Together this demonstrates that post-MI IL-6 is mainly derived from activated CFs and is controlled by T-cell derived adenosine. Purinergic metabolic cooperation between CFs and T-cells is a novel mechanism with therapeutic potential which modulates IL6 formation by the heart.
Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening
Authors: Sigrún Thorsteinsdóttir, Gauti K. Gíslason, Thor Aspelund, Sæmundur Rögnvaldsson, Jón Þórir Óskarsson, Guðrún Á Sigurðardóttir, Ásdís R. Þórðardóttir, Brynjar Viðarsson, Páll T. Önundarson, Bjarni A. Agnarsson, Margrét Sigurðardóttir, Ingunn Þorsteinsdóttir, Ísleifur Ólafsson, Elías Eyþórsson, Ásbjörn Jónsson, Oscar Berlanga, Malin Hultcrantz, Brian G. M. Durie, Thorvardur J. Löve, Stephen Harding, Ola Landgren, Sigurður Y. Kristinsson
Journal: Nature Medicine (2023)
Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons—Reply
Authors: Carol M. Mangione, Wanda Nicholson, James Stevermer
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Causal effects on complex traits are similar for common variants across segments of different continental ancestries within admixed individuals
Authors: Kangcheng Hou, Yi Ding, Ziqi Xu, Yue Wu, Arjun Bhattacharya, Rachel Mester, Gillian M. Belbin, Steve Buyske, David V. Conti, Burcu F. Darst, Myriam Fornage, Chris Gignoux, Xiuqing Guo, Christopher Haiman, Eimear E. Kenny, Michelle Kim, Charles Kooperberg, Leslie Lange, Ani Manichaikul, Kari E. North, Ulrike Peters, Laura J. Rasmussen-Torvik, Stephen S. Rich, Jerome I. Rotter, Heather E. Wheeler, Genevieve L. Wojcik, Ying Zhou, Sriram Sankararaman, Bogdan Pasaniuc
Journal: Nature Genetics (2023)
Association of alcohol consumption with disease activity and health‐related quality of life in rheumatoid arthritis: comment on the article by Alfredsson et al
Authors: Gang Wang, Ning Zhuo, Ying Luo, Leixi Xue, Mei Tang, Zhichun Liu
Journal: Arthritis & Rheumatology (2023)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Microbial metabolites as modulators of the infant gut microbiome and host-microbial interactions in early life
Authors: Henrik M. Roager, Catherine Stanton, Lindsay J. Hall
Journal: Gut Microbes (2023)

The development of infant gut microbiome is a pivotal process affecting the ecology and function of the microbiome, as well as host health. While the establishment of the infant microbiome has been of interest for decades, the focus on gut microbial metabolism and the resulting small molecules (metabolites) has been rather limited. However, technological and computational advances are now enabling researchers to profile the plethora of metabolites in the infant gut, allowing for improved understanding of how gut microbial-derived metabolites drive microbiome community structuring and host-microbial interactions. Here, we review the current knowledge on development of the infant gut microbiota and metabolism within the first year of life, and discuss how these microbial metabolites are key for enhancing our basic understanding of interactions during the early life developmental window.
A Bioinspired Gelatin–Amorphous Calcium Phosphate Coating on Titanium Implant for Bone Regeneration
Authors: Yanhuizhi Feng, Di Wu, Jennifer Knaus, Sascha Keßler, Bing Ni, ZongKun Chen, Johnathan Avaro, Rui Xiong, Helmut Cölfen, Zuolin Wang
Journal: Advanced Healthcare Materials (2023)

Biocompatible and bio-active coatings can enhance and accelerate osseointegration via chemical binding onto substrates. Amorphous calcium phosphate (ACP) has been shown as a precursor to achieve mineralization in vertebrates and invertebrates under the control of biological macromolecules. This work presents a simple bioinspired Gelatin-CaPO
SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study
Authors: Mikael Knip, Anna Parviainen, Maaret Turtinen, Anna But, Taina Härkönen, Jussi Hepojoki, Tarja Sironen, Rommel Iheozor-Ejiofor, Hasan Uğurlu, Kalle Saksela, Johanna Lempainen, Jorma Ilonen, Olli Vapalahti
Journal: The Lancet Diabetes & Endocrinology (2023)
Endoscopic full-thickness plication for the treatment of gastroesophageal reflux after peroral endoscopic myotomy: a randomized sham-controlled study
Authors: Amit Maydeo, Gaurav Patil, Nagesh Kamat, Ankit Dalal, Amol Vadgaonkar, Sanil Parekh, Rajen Daftary, Sehajad Vora
Journal: Endoscopy (2023)

BACKGROUND : Endoscopic full-thickness plication (EFTP) has shown promising results in gastroesophageal reflux disease (GERD), but its efficacy in GERD after peroral endoscopic myotomy (POEM) is unclear. METHODS : In a prospective, randomized trial of post-POEM patients dependent on proton pump inhibitors (PPIs) for documented GERD, patients underwent EFTP (plication to remodel the gastroesophageal flap valve) or an endoscopic sham procedure (positioning of the EFTP device, but no stapling). The primary end point was improvement in acid exposure time (AET) < 6 % (3 months). Secondary end points included improvement in esophagitis (3 months), GERD Questionnaire (GERDQ) score (3 and 6 months), and PPI usage (6 months). RESULTS : 60 patients were randomized (30 in each group). At 3 months, a significantly higher proportion of patients achieved improvement in AET < 6 % in the EFTP group compared with the sham group (69.0 % [95 %CI 52.1-85.8] vs. 10.3 % [95 %CI 0-21.4], respectively). EFTP was statistically superior to sham (within-group analysis) in improving esophageal AET, DeMeester Score, and all reflux episodes (P < 0.001). A nonsignificant improvement in esophagitis was noted in the EFTP group (P = 0.14). Median GERDQ scores (3 months) were significantly better (P < 0.001) in the EFTP group, and the same trend continued at 6 months. A higher proportion of patients in the sham group continued to use PPIs (72.4 % [95 %CI 56.1-88.7] vs. 27.6 % [95 %CI 11.3-43.8]). There were no major adverse events in either group. CONCLUSION : EFTP improved post-POEM GERD symptoms, 24-hour pH impedance findings with normalization in one-third, and reduced PPI usage at 6 months.
Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer
Authors: Jennifer K. Plichta, Samantha M. Thomas, Daniel F. Hayes, Mariana Chavez-MacGregor, Kimberly Allison, Jennifer de los Santos, Amy M. Fowler, Armando E. Giuliano, Priyanka Sharma, Benjamin D. Smith, Elizabeth van Eycken, Stephen B. Edge, Gabriel N. Hortobagyi
Journal: Journal of Clinical Oncology (2023)

Given the heterogeneity and improvement in outcomes for metastatic breast cancer (MBC), we developed a staging system that refines prognostic estimates for patients with metastatic cancer at the time of initial diagnosis, de novo MBC (dnMBC), on the basis of survival outcomes and disease-related variables.
Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
Authors: Vandana Sachdev, Kavita Sharma, Steven J. Keteyian, Charina F. Alcain, Patrice Desvigne-Nickens, Jerome L. Fleg, Viorel G. Florea, Barry A. Franklin, Maya Guglin, Martin Halle, Eric S. Leifer, Gurusher Panjrath, Emily A. Tinsley, Renee P. Wong, Dalane W. Kitzman
Journal: Circulation (2023)

Heart failure with preserved ejection fraction (HFpEF) is one of the most common forms of heart failure; its prevalence is increasing, and outcomes are worsening. Affected patients often experience severe exertional dyspnea and debilitating fatigue, as well as poor quality of life, frequent hospitalizations, and a high mortality rate. Until recently, most pharmacological intervention trials for HFpEF yielded neutral primary outcomes. In contrast, trials of exercise-based interventions have consistently demonstrated large, significant, clinically meaningful improvements in symptoms, objectively determined exercise capacity, and usually quality of life. This success may be attributed, at least in part, to the pleiotropic effects of exercise, which may favorably affect the full range of abnormalities—peripheral vascular, skeletal muscle, and cardiovascular—that contribute to exercise intolerance in HFpEF. Accordingly, this scientific statement critically examines the currently available literature on the effects of exercise-based therapies for chronic stable HFpEF, potential mechanisms for improvement of exercise capacity and symptoms, and how these data compare with exercise therapy for other cardiovascular conditions. Specifically, data reviewed herein demonstrate a comparable or larger magnitude of improvement in exercise capacity from supervised exercise training in patients with chronic HFpEF compared with those with heart failure with reduced ejection fraction, although Medicare reimbursement is available only for the latter group. Finally, critical gaps in implementation of exercise-based therapies for patients with HFpEF, including exercise setting, training modalities, combinations with other strategies such as diet and medications, long-term adherence, incorporation of innovative and more accessible delivery methods, and management of recently hospitalized patients are highlighted to provide guidance for future research.
Functionalized Rhodium Nanoparticles as Antimicrobial Agents for Treatment of Drug‐Resistant Skin and Soft Tissue Infections
Authors: Qingqin Tan, Zhenxing Chen, Lei Liu, Xi Huang
Journal: Advanced Healthcare Materials (2023)

Skin and soft tissue infections (SSTIs) are among the most common bacterial infections reported in outpatients. Drug-resistant bacteria are the major cause of treatment failure and increased mortality rate in patients with SSTIs, posing significant challenges to human health. In this study, new-generation rhodium nanoplates (RhNPs) and glycol chitosan- and polydopamine-functionalized RhNPs (Rh@GCS) are developed for the treatment of drug-resistant SSTIs. RhNPs exhibited favorable antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Ag-resistant MRSA. The modified Rh@GCS exhibited enhanced antibacterial activity and can directly kill various drug-resistant bacteria by increasing the permeability of cell membranes, including gram-positive MRSA and gram-negative multidrug-resistant Escherichia coli (E.coli) and Pseudomonas aeruginosa (PA). Moreover, Rh@GCS effectively inhibited bacterial growth and promoted the healing of skin lesions in MRSA-induced SSTI mouse models. These results suggest that Rh@GCS is a promising nonantibiotic antimicrobial agent for the treatment of drug-resistant SSTIs.
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
Authors: Juliana M. Bue-Valleskey, Christof M. Kazda, Chenchen Ma, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Axel Haupt, Juan P. Frias
Journal: Diabetes Care (2023)

Basal insulin Fc (BIF) (insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed the safety and efficacy of BIF versus degludec in insulin-naive patients with type 2 diabetes (T2D) previously treated with oral antihyperglycemic medications.
Highlights From the <i>Circulation</i> Family of Journals
Authors: Yoshitaka Kimura, Marta De Riva, Micaela Ebert, Claire Glashan, Adrianus Wijnmaalen, Sebastiaan Piers, Olaf Dekkers, Serge Trines, Katja Zeppenfeld, Thomas Cascino, Monica Colvin, David Lanfear, Blair Richards, Shokoufeh Khalatbari, Douglas Mann, Wendy Taddei-Peters, Neal Jeffries, Daphne Watkins, Garrick Stewart, Keith Aaronson, Aishwarya Raja, Rishi Wadhera, Eunhee Choi, Siyan Chen, Changyu Shen, Jose Figueroa, Robert Yeh, Eric Secemsky, Yongjian Liu, James Thackeray, Gyu Seong Heo, Johanna Diekmann, Tim Kinnaird, Sean Gallagher, Vasim Farooq, Majd Protty, Liam Back, Peadar Devlin, Richard Anderson, Andrew Sharp, Peter Ludman, Samuel Copt, Mamas Mamas, Nick Curzen
Journal: Circulation (2023)

Racial inequities in accessing advanced heart failure therapies are reported in Circulation: Heart Failure.Outpatient clinic-based vascular procedure outcomes are compared with those done in a hospital setting in Circulation: Cardiovascular Quality and Outcomes.Immune cell imaging using nuclear methods is reviewed in Circulation: Cardiovascular Imaging.Finally, temporal trends in left main percutaneous coronary intervention from the United Kingdom are described in Circulation: Cardiovascular Interventions.
Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study
Authors: Huan Wang, Ruth L.M. Cordiner, Yu Huang, Louise Donnelly, Simona Hapca, Andrew Collier, John McKnight, Brian Kennon, Fraser Gibb, Paul McKeigue, Sarah H. Wild, Helen Colhoun, John Chalmers, John Petrie, Naveed Sattar, Thomas MacDonald, Rory J. McCrimmon, Daniel R. Morales, Ewan R. Pearson, Luke Blackbourn, Scott Cunningham, Fraser Gibb, Graham Leese, Robert Lindsay, David McAllister, Stuart McGurnaghan, Sam Philip
Journal: Diabetes Care (2023)

To assess the real-world cardiovascular (CV) safety for sulfonylureas (SU), in comparison with dipeptidyl peptidase 4 inhibitors (DPP4i) and thiazolidinediones (TZD), through development of robust methodology for causal inference in a whole nation study.A cohort study was performed including people with type 2 diabetes diagnosed in Scotland before 31 December 2017, who failed to reach HbA1c 48 mmol/mol despite metformin monotherapy and initiated second-line pharmacotherapy (SU/DPP4i/TZD) on or after 1 January 2010. The primary outcome was composite major adverse cardiovascular events (MACE), including hospitalization for myocardial infarction, ischemic stroke, heart failure, and CV death. Secondary outcomes were each individual end point and all-cause death. Multivariable Cox proportional hazards regression and an instrumental variable (IV) approach were used to control confounding in a similar way to the randomization process in a randomized control trial.Comparing SU to non-SU (DPP4i/TZD), the hazard ratio (HR) for MACE was 1.00 (95% CI: 0.91-1.09) from the multivariable Cox regression and 1.02 (0.91-1.13) and 1.03 (0.91-1.16) using two different IVs. For all-cause death, the HR from Cox regression and the two IV analyses was 1.03 (0.94-1.13), 1.04 (0.93-1.17), and 1.03 (0.90-1.17).Our findings contribute to the understanding that second-line SU for glucose lowering are unlikely to increase CV risk or all-cause mortality. Given their potent efficacy, microvascular benefits, cost effectiveness, and widespread use, this study supports that SU should remain a part of the global diabetes treatment portfolio.
Macrophages‐Cancer Membrane‐Encapsulated Metal−Organic Frameworks with Copper‐Depleting Moiety for Mitochondria‐Targeted Therapeutics
Authors: Weiqun Li, Mingjie Dong, Yingchun Li, Haifeng Dong
Journal: Advanced Healthcare Materials (2023)

Mitochondria-targeted therapeutics are an attractive approach against energy-dependent cancer. However, effective mitochondria organelle therapeutics agents are still highly desirable. Herein, a mitochondria-targeted therapeutics platform, termed CDM@MUiO-DP@MCHM, consisting of macrophages-cancer hybrid membrane (MCHM) encapsulated MUiO-66 metal-organic frameworks (MOFs) is reported, which is loaded with microRNA (miRNA) biomarker detection probe (DP) for cancer diagnosis and copper-depleting moiety (CDM) for mitochondrial copper depletion to suppress cancer growth. Using nude mice bearing MCF-7 as model, after injecting intravenously via the caudal vein of mice, the encapsulation of MCHM can not only greatly enhance the cancer homing-targeting ability of the nanoparticles (NPs) but also endows the NPs the immune escape capacity to extend the circulation time. The miRNA-21 biomarker can be detected by the fluorescence signal for diagnosis, while the CDM induced energy deficiency and compromised mitochondria membrane potential, leading to apoptosis of the cancer cell. The good performance of CDM@MUiO-DP@MCHM suggest the great potential mitochondria organelle therapeutics.